NCT04928508View on ClinicalTrials.gov

Advanced or Recurrent Solid Tumors Treated With SHetA2

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

June 30, 2026

Conditions
Solid Tumor, Adult
Interventions
DRUG

OK-1

"OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"

Trial Locations (1)

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Oklahoma

OTHER